echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Positive top-line results from Pfizer's one-year Phase 3 trial of Etrasimod in patients with ulcerative colitis show Best-in-Class potential

    Positive top-line results from Pfizer's one-year Phase 3 trial of Etrasimod in patients with ulcerative colitis show Best-in-Class potential

    • Last Update: 2022-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    In this 52-week study (also known as ELEVATE UC 52), patients treated with etrasimod achieved statistically significant co-primary endpoints of clinical remission at both weeks 12 and 52 compared with placebo Sexual improvement


    This global phase 3, multicenter, randomized, double-blind, placebo-controlled study enrolled 433 patients with ulcerative colon who had failed or were intolerant to at least one prior conventional therapy, biologics, or Janus kinase (JAK) inhibitors.


    The full results of the study will be used for scientific journal publication and reporting


    Etrasimod is being developed by Arena Pharmaceuticals, which Pfizer recently completed its acquisition of, and Genting Xinyao acquired the exclusive rights to develop, manufacture and commercialize etrasimod from Arena in Greater China and South Korea in 2017


    "We are delighted to see the positive top-line results of etrasimod again, which shows its promise as a best-in-class therapy


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.